The Effects of Cannabidiol and Homotaurine in Patients With Mild Cognitive Impairment
Status:
Recruiting
Trial end date:
2022-12-20
Target enrollment:
Participant gender:
Summary
A Randomized Clinical Trial that will compare the effects of Cannabidiol and Homotaurine in
cognition and mental health in patients with Mild Cognitive Impairment and APOE ε4 carriers.
Ninety patients will be recruited and they will be randomly distributed in three groups. The
first group will receive treatment with Cannabidiol 5%, the second group will receive
treatment with Vivimind and the third group will not receive any treatment. The three groups
will be compared by using an extensive neuropsychological examination and biomarkers' results
from cerebrospinal fluid and blood
Phase:
Phase 4
Details
Lead Sponsor:
Aristotle University Of Thessaloniki
Collaborator:
Greek Alzheimer's Association and Related Disorders